Transaction in Own Shares

Fidelity Emerging Markets Limited repurchased and cancelled 16,713 shares on 02 January 2026 at an average price of 1,084.89 GBp (low 1,082.00; high 1,085.00). After the cancellation the issued share capital is 53,532,188, with 9,025,940 shares held in treasury and total voting rights of 44,506,249; the repurchase is immaterial in scale (~0.03% of issued capital) but signals continued shareholder returns by the company.

Analysis

Market structure: This token repurchase (16,713 shares, ~0.03% of issued capital) is economically immaterial but signals continued capital-return willingness by Fidelity Emerging Markets Limited (the Company). Direct beneficiaries are existing holders via marginal float compression and potential discount tightening versus NAV; passive EM ETF holders (EEM, VWO) are neutral-to-negative as capital is concentrated in the closed‑end vehicle. Liquidity in the Company’s shares may tighten slightly (higher bid/ask) given 9.0m shares already in treasury (~16.9% of issued), but cross-asset contagion to bonds, FX or commodities is negligible absent a larger program.

Risk assessment: Immediate (days) effect is near-zero price move; short-term (weeks–months) upside is conditional on scale — if repurchases persist at >£10k–£50k/month the discount could compress 3–8% within 3–12 months; long-term (>12 months) depends on EM NAV performance and management’s allocation. Tail risks include a sharp EM NAV shock (currency devaluation, geopolitical event) that widens discounts >15% and renders buybacks value-destructive, and governance risk from concentrated treasury shares reducing minority protections. Hidden dependencies: buybacks funded from liquid assets reduce buffer for dividends or opportunistic buys; monitoring monthly RNS is critical as token buys are PR rather than value-creating.

Trade implications: Direct play — establish a small tactical long in Fidelity Emerging Markets Limited equal to 1–2% of total portfolio, scaled in if discount to NAV >6% or price drops to ≤1,040 GBp (≈‑4% from this trade price) with 6–12 month horizon and target IRR 8–15%. Pair trade — long the Company vs short VWO or EEM (notional neutral EM beta) to capture discount convergence; size 0.5–1% net exposure. Options — hedge EM beta with a 3‑month put spread on EEM (buy 5% OTM, sell 10% OTM) sized to cover downside risk for the position.

Contrarian angles: The market may over-interpret a token buyback as a durable capital-return program; consensus upside is underdone if management scales purchases to >0.5% of market cap quarterly but overdone if buys remain token. Historical parallels: UK closed‑end funds that executed sustained buybacks (not token) saw discount compressions of 5–12% over 6–18 months; token repurchases often produced no lasting alpha. Unintended consequence — rising treasury stock can reduce free float and liquidity, increasing volatility and potentially widening discounts if investor exit flows accelerate.

Key Decisions for Investors

• Establish a small tactical long (1–2% of portfolio) in Fidelity Emerging Markets Limited (Fidelity Emerging Markets Limited, UK-closed end) only if discount to NAV exceeds 6% or price falls to ≤1,040 GBp; hold 6–12 months, take profits if discount narrows >5% or price gains 12–15%.
• Implement a pair trade: long the Company vs short Vanguard FTSE Emerging Markets ETF (VWO) or iShares MSCI Emerging Markets ETF (EEM) to neutralize EM beta; size at 0.5–1% net notional with monthly rebalancing and target discount convergence within 9–12 months.
• Buy a 3‑month put spread on EEM (buy 5% OTM, sell 10% OTM) sized to cover downside tail risk for the exposure (cost-limited hedge) if establishing or increasing position — enter if implied vol < historical vol +2pp.
• Avoid increasing passive EM allocations ahead of the Company’s next 30–90 day RNS; if the Company announces a formal, material buyback program (>0.5% of market cap per quarter), increase exposure to active/closed-end EM managers by 1–3%.